Carl Zeiss Meditec performed well in the first nine months 2008/2009
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ Consolidated revenue increases by 7.2 percent to EUR 478.5 million -cash flow from operating activities doubles in the reporting period(JENA, 13 August 2009) Despite persistently difficult economicconditions, Carl Zeiss Meditec AG held its own again in the firstnine months of 2008/2009 (1 October 2008 - 30 June 2009). Thanks toits broad portfolio and global orientation, the company generatedsolid growth of 7.2 percent to EUR 478.5 million. Carl Zeiss Meditecincreased earnings before interest and taxes disproportionately torevenue, by 11.0 percent to EUR 53.6 million (previous year: EUR 48.3million)."These results prove that our operations have taken the right path.Thanks to solid consolidated net income, to which all business unitscontributed, and strong receivables management, we managed to doublethe operating cash flow in the first nine months to EUR 58.6 million.This financial stability lends us competitive strength", explains Dr.Michael Kaschke, President and CEO of Carl Zeiss Meditec AG.Due to a lower financial result following a fall in the interestrates on capital investments, the consolidated net income afterminority interests from October 2008 to June 2009, at EUR 32.5million, was lower than the prior-year value (EUR 36.4 million).Earnings per share after minority interests totalled EUR 0.40(previous year: EUR 0.45) in the first nine months of 2008/2009.Growth course in all business unitsThe "Ophthalmic Systems" strategic business unit, which primarilydeals in diagnostic and treatment systems for ophthalmology, recordeda satisfactory revenue increase of 13.2 percent during the reportingperiod to EUR 232.2 (previous year: EUR 205.1) million. Here thecompany benefitted, in particular, from its innovative products andthe currency development of the US dollar and the yen against theeuro.In the area of implants and consumables for ophthalmology, the"Surgical Ophthalmology" strategic business unit, revenue grew by 5.3percent to EUR 61.6 (previous year: EUR 58.4) million, which wasprimarily due to higher revenues with innovative intraocular lenses.Due to the reluctance in some cases to invest in the hospital sector,revenue in the Microsurgery SBU only increased slightly in the firstnine months to EUR 184.7 (previous year: EUR 183.0) million. Thisgrowth was driven by the innovative surgical microscopes OPMI®Pentero® for neurosurgery and OPMI Lumera® for ophthalmic surgery.The "Microsurgery" SBU accounted for a 38.6 percent share of revenue(previous year: 41.0 percent), while the "Ophthalmic Systems" SBUcontributed 48.5 percent (previous year: 45.9 percent) and the"Surgical Ophthalmology" SBU the remaining 12.9 percent (previousyear: 13.1 percent).Asia/Pacific shows high growth ratesCarl Zeiss Meditec continued to generate high growth rates in the"Asia/Pacific" region during the first nine months of 2008/2009.Revenue in this region rose by 20.2 percent year-on-year to EUR 128.2million (previous year: EUR 106.7 million). In addition to theJapanese market, the Indian market also contributed to thisdevelopment. The region's share of revenue increased slightly to 26.8percent, compared with 23.9 percent in the previous year.The "Americas" region was once again the strongest generator of salesin the first nine months of 2008/2009. Here revenue increased by 9.6percent from EUR 151.2 million to EUR 165.7 million. Positiveinfluences came from sales of innovative diagnostic equipment andsurgical microscopes. In addition, the same period of the previousyear was significantly influenced by economic turbulence, especiallyin the United States. The region's share of revenue increasedslightly to 34.7 percent, compared with 33.8 percent in the previousyear. The proportion of Carl Zeiss Meditec's revenue generated byGermany as a regional market decreased compared with the same periodof the previous year from 8.9 percent to 8.3 percent.The sales drivers in the "Europe, Middle East and Africa" (EMEA)region were diagnostic systems, surgical microscopes and intraocularlenses. Revenue amounted to EUR 144.8 million (previous year: EUR149.0 million) in the reporting period. The proportion ofconsolidated revenue generated by this region decreased from 33.4percent to 30.2 percent year-on-yearPositive outlook for financial year 2008/2009Given a strong order intake at the end of Q3 of this financial year,Carl Zeiss Meditec expects at least five percent revenue growth withstable profitability for financial year 2008/2009.President and CEO Dr. Kaschke explains: "However, it is the medium-and long-term outlook that is more important to us than short-termdevelopments: for our objective is to achieve sustainable profitablegrowth. In the longer-term we are well-equipped, thanks to ourstrategic orientation, our technological innovative strength and ourfinancial muscle, to continue our investment even now intocustomer-oriented innovations and into strengthening our sales andservice structures. This puts us in a position to successfullyovercome the challenges that arise in the near future."Press contacts:Eva SesselmannCorporate CommunicationsCarl Zeiss Meditec AGGöschwitzer Straÿe 51-5207745 JenaPhone: +49 3641 220-331Phone: +49 3641 220-112E-mail: press(at)meditec.zeiss.com Patrick KoflerInvestor RelationsCarl Zeiss Meditec AGGöschwitzer Straÿe 51-5207745 JenaPhone: +49 3641 220-106Phone: +49 3641 220-117E-mail: investors(at)meditec.zeiss.comBrief profileCarl Zeiss Meditec AG (ISIN: DE 0005313704) is listed in the Tec-DAXof the Deutsche Börse and is one of the world's leading medicaltechnology suppliers.The company supplies innovative technologies and application-orientedsolutions designed to help doctors improve the quality of life oftheir patients. The Company offers complete solutions, includingimplants and consumables, to diagnose and treat ophthalmic diseases.The company creates innovative visualisation solutions in the fieldof microsurgery. Carl Zeiss Meditec's medical technology portfolio isrounded off by promising future technologies, such as intraoperativeradiation therapy.In the 2007/2008 (30 September) financial year the 2,100 employeesgenerated revenue of approximately 600 EUR million. The registeredoffice of Carl Zeiss Meditec is located in Jena, Germany. The companyhas subsidiaries in Germany and abroad; more than 50 percent of itsemployees are based in the USA, Japan, Spain and France.35 percent of Carl Zeiss Meditec shares are in free float. Theremaining 65 percent are held by Carl Zeiss AG, one of the world'sleading groups engaged in the optical and opto-electronics industry.The five independently run business segments of Carl Zeiss AG operatein the future markets "Medical and Research Solutions", "IndustrialSolutions" and "Lifestyle Products". The head office of Carl Zeiss AGis in Oberkochen, Germany. In financial year 2007/08 (balance sheetdate 30 September) the group posted sales of around EUR 2.7 billion.Carl Zeiss has a total workforce of about 13,000 in over 30countries, over 8,000 of them in Germany.Further information: http://www.meditec.zeiss.de --- End of Message ---Carl Zeiss Meditec AGGoeschwitzer Strasse 51-52 Jena GermanyWKN: 531370; ISIN: DE0005313704; Index: Prime All Share, TECH All Share, TecDAX;Listed: Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Prime Standard in Frankfurter Wertpapierbörse, Regulierter Markt in Frankfurter Wertpapierbörse;
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 13.08.2009 - 01:14 Uhr
Sprache: Deutsch
News-ID 1003194
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
London
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 112 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Carl Zeiss Meditec performed well in the first nine months 2008/2009
"
steht unter der journalistisch-redaktionellen Verantwortung von
Carl Zeiss Meditec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
